These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26320435)

  • 1. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
    Tu C; Zheng F; Wang JY; Li YY; Qian KQ
    Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
    Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
    BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
    Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
    Sun C; Ansari D; Andersson R; Wu DQ
    World J Gastroenterol; 2012 Sep; 18(35):4944-58. PubMed ID: 23002368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.
    Hu J; Zhao G; Wang HX; Tang L; Xu YC; Ma Y; Zhang FC
    J Hematol Oncol; 2011 Mar; 4():11. PubMed ID: 21439076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
    Sultana A; Smith CT; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
    J Clin Oncol; 2007 Jun; 25(18):2607-15. PubMed ID: 17577041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
    Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
    World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Tian W; Zhang L; Liu X; Ma X; Wang R
    PLoS One; 2023; 18(3):e0282360. PubMed ID: 36862702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
    Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
    BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
    Banu E; Banu A; Fodor A; Landi B; Rougier P; Chatellier G; Andrieu JM; Oudard S
    Drugs Aging; 2007; 24(10):865-79. PubMed ID: 17896834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
    Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
    Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
    Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z
    Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
    Xiao BY; Wang BC; Lin GH; Li PC
    Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.